Abstract: A client device presents a user interface including a macro entry field for defining a macro indicator from a plurality of macro indicators and transmits the macro indicator. A server stores a database of macro-based diagnoses, each macro-based diagnosis associated with one or more elements of an accession, and one or more specimens associated with the accession. The server also receives the macro indicator from the client device, retrieves an initial diagnosis from the database of macro-based diagnoses responsive to the macro indicator, and transmits the initial diagnosis. The client device, receives the initial diagnosis, pre-populates one or more text boxes on the user interface with information from the initial diagnosis, and enables the user to edit the pre-populated one or more text boxes.

Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p,R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods ace provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.

Abstract: A client device presents a user interface including a macro entry field for defining a macro indicator from a plurality of macro indicators and transmits the macro indicator. A server stores a database of macro-based diagnoses, each macro-based diagnosis associated with one or more elements of an accession, and one or more specimens associated with the accession. The server also receives the macro indicator from the client device, retrieves an initial diagnosis from the database of macro-based diagnoses responsive to the macro indicator, and transmits the initial diagnosis. The client device, receives the initial diagnosis, pre-populates one or more text boxes on the user interface with information from the initial diagnosis, and enables the user to edit the pre-populated one or more text boxes.

Abstract: An aluminum alloy fin stock material comprising about 0.9-1.2 wt. % Si, 0.3-0.5 wt. % Fe, 0.20-0.40 wt. % Cu, 1.0-1.5 wt. % Mn, 0-0.1% Mg and 0.0-3.0% Zn, with remainder Al and impurities at ?0.15 wt. %. The aluminum alloy fin stock material is produced in a form of a sheet by a process comprising the steps of direct chill casting an ingot, hot rolling the ingot after the direct chill casting, cold rolling the aluminum alloy to an intermediate thickness, inter-annealing the aluminum alloy cold rolled to an intermediate thickness at a temperature between 200 and 400° C., and cold rolling the material after inter-annealing to achieve % cold work (% CW) of 20 to 40%. The aluminum alloy fin stock material possesses an improved combination of one or more of pre- and/or post-brazes strength, conductivity, sag resistance and corrosion potential. It is useful for fabrication of heat exchanger fins.

Abstract: An electronic device manufacturing system that includes a process tool and a tool server coupled to the process tool and comprising a communication node and an evaluation system. The communication node is configured to obtain one or more attributes from an evaluation system and provide a monitoring device comprising a data collection plan that is based on the one or more attributes. The communication node is further configured to register the monitoring device with a process tool. The communication node is further configured to receive, from the process tool, data based on the data collection plan and send the received data to the evaluation system.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: An electronic device manufacturing system that includes a process tool and a tool server coupled to the process tool and comprising a communication node and an evaluation system. The communication node is configured to obtain one or more attributes from an evaluation system and provide a monitoring device comprising a data collection plan that is based on the one or more attributes. The communication node is further configured to register the monitoring device with a process tool. The communication node is further configured to receive, from the process tool, data based on the data collection plan and send the received data to the evaluation system.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof based on results from long term clinical studies.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: A client device presents a user interface including a macro entry field for defining a macro indicator from a plurality of macro indicators and transmits the macro indicator. A server stores a database of macro-based diagnoses, each macro-based diagnosis associated with one or more elements of an accession, and one or more specimens associated with the accession. The server also receives the macro indicator from the client device, retrieves an initial diagnosis from the database of macro-based diagnoses responsive to the macro indicator, and transmits the initial diagnosis. The client device, receives the initial diagnosis, pre-populates one or more text boxes on the user interface with information from the initial diagnosis, and enables the user to edit the pre-populated one or more text boxes.

Abstract: The present application provides a method of isolating highly purified and characterized exosomes from tissue and cellular sources for the purpose of regenerative medicine as well as a composition including an exosome or an exosomal compound or component. The composition is used for the therapeutic treatment of various physiological damages and diseases, including skin or cutaneous damages/diseases, cardiovascular diseases, ophthalmic diseases, neurological diseases, viral diseases, and cancer among other damages and diseases.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: A method for removing VOCs from exhaust gases of a CIPP curing process, the method including the steps of: (a) positioning an exhaust conduit to capture the exhaust gases; (b) elevating the temperature of at least a portion of the exhaust gases and passing the exhaust gases over a catalyst containing substrate to form a devolitized gas stream; and (c) directing the devolitized gas stream to an exhaust stack.

Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Abstract: The subject matter described herein provides non-invasive patch stripping methods for the collection of a skin sample. The patch stripping method includes applying and removing at least one adhesive patch, provided that a skin sample is adhered to the adhesive patch after removal. The at least one adhesive patch is supplied in an adhesive skin sample collection kit. Optionally, the adhesive skin sample collection kit further comprises a sample collector and/or instructions for use.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.